Last reviewed · How we verify
NCT03927235
The Diagnostic Yield and Safety of Transbronchial Cryobiopsy in Different Freezing Time in the Diffuse Parenchymal Lung Diseases
NA trial testing Transbronchial Cryobiopsy in Transbronchial Cryobiopsy in 80 participants. Status unknown.
15 May 2020
Quick facts
| Lead sponsor | Guangzhou Institute of Respiratory Disease |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 80 |
| Start date | 16 May 2019 |
| Primary completion | 15 May 2020 |
| Estimated completion | 15 May 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Transbronchial Cryobiopsy
Conditions studied
- Transbronchial Cryobiopsy — all drugs for Transbronchial Cryobiopsy →
- Freezing Time — all drugs for Freezing Time →
- Diagnostic Yield — all drugs for Diagnostic Yield →
- Safety — all drugs for Safety →
Sponsor
Guangzhou Institute of Respiratory Disease
Who can join
Adults 18 to 70, any sex, with Transbronchial Cryobiopsy or Freezing Time. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Transbronchial cryobiopsy in different freezing time is performed in patients with undefined diffuse parenchymal lung diseases, and assess the diagnostic yield and safety.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03927235
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transbronchial Cryobiopsy
Trials testing the same drug.
- NCT04727190 — The Efficacy and Safety of TBCB vs TBFB in Diagnosis of GGO · NA · unknown
Other recruiting trials for Transbronchial Cryobiopsy
Currently open trials in the same condition.
- NCT06251687 — Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis · NA · recruiting
Other Guangzhou Institute of Respiratory Disease trials
Trials by the same sponsor.
- NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
- NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
- NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
- NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
- NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03927235 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
- Last refreshed: 30 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03927235.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing